Anticancer

Gallic acid
Catalog No: CFN99624

Gallic acid, is a histone acetyltransferase inhibitor and a potent inhibitor of brush border sucrase and other disaccharidases, which has powerful antioxidant, anti-tumor, and anti-tyrosinase activities. It can potentially interfere with the digestive functions of the intestine. It can efficiently block neuronal cell death by downregulating the expression of cytokines and the in vivo levels of NF-κB acetylation, is a possible therapeutic approach for alleviating the inflammatory progression of Alzheimer disease.
Pachymic acid
Catalog No: CFN99590

Pachymic acid has sedative-hypnotic, cardioprotective,antioxidant, and anti-inflammatory activities, it has hypoglycemic activity ,can stimulate glucose uptake, GLUT4 gene expression and translocation, and promoting triglyceride accumulation in adipocytes. Pachymic acid may inhibit proliferation and invasion of ovarian carcinoma cell through decreasing β-catenin and COX-2 expression and increasing E-cadherin exprssion. Pachymic acid is suggested to prevent the complications of oral diseases such as inflammation and alveolar destruction of the oral cavity.
Pseudohypericin
Catalog No: CFN99591

Pseudohypericin has photocytotoxic, and antiretroviral activities, it has potential therapeutic value in diseases such as AIDS. Pseudohypericin can inhibit LPS-stimulated PGE2 and NO in mouse macrophages by potentiating suppressor of cytokine signaling 3 (SOCS3) expression, it has anti-tumor potential.
Sanggenone C
Catalog No: CFN99593

Sanggenone C inhibits tumor cellular proteasomal activity and cell viability, via induction of cell cycle arrest and cell death , inhibiting the proteasome function. It inhibited NO production and iNOS expression by suppressing NF-κB activity and IκBα activation; inhibited TNF-alpha -stimulated PMN-HSC adhesion and expression of VCAM-1 by suppressing the activation of NF-kappaB.
Sennidin A
Catalog No: CFN99597

Sennidin A, has two hydroxyanthraquinone-like moieties, exerts inhibition on NS3 helicase with IC50 values of 0.8 uM. Sennidin A in combination with necrosis inducing drugs/therapies may generate synergetic tumoricidal effects on solid malignancies by means of primary debulking and secondary cleansing process. It stimulates glucose incorporation in the phosphatidylinositol 3-kinase (PI3K)- and Akt-dependent in rat adipocytes, but in the IR/IRS1-independent manner.